Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B Dec 4, 2008
At week 48, amino acid substitutions within HBV DNA polymerase associated with phenotypic resistance to tenofovir DF or other drugs to treat HBV infection had not developed in any of the patients. Tenofovir DF produced a similar HBV DNA response in patients who had previously received lamivudine and in those who had not. (New England Journal of Medicine)
An Advance On New Generations Of Chemotherapy And Antiviral Drugs Sep 13, 2008
In the article, Anthony J. Berdis updates and reviews worldwide research efforts to develop drugs that target DNA polymerases, the enzymes responsible for assembling DNA from its component parts ... Berdis et al. DNA Polymerases as Therapeutic Targets ... Illustration of DNA polymerase moving along the length of a DNA strand. (Science Daily)
Application Notes Aug 29, 2008
In preliminary studies to characterize the KOD1 DNA polymerase, researchers found that the enzyme had fidelity comparable to Pfu DNA polymerase, but with an extension rate (referred to as speed) 5 tim 00004000 es higher and processivity 10 to 15 times higher than the Pfu enzyme (Takagi 1997). When amplifying DNA for cloning, high fidelity DNA polymerases, such as KOD polymerase, are recommended. (Nature News Service)
Viread Approved for Hepatitis B Aug 14, 2008
A once-daily tablet, Viread blocks an enzyme called HBV DNA polymerase, which is needed by the hepatitis B virus to replicate in liver cells. HealthDay. (MEDLINEplus)
FDA approves Gilead's Viread for hepatitis treatment Aug 13, 2008
Foster City-based Gilead (NASDAQ: GILD) said Viread is a once-daily tablet that works by blocking HBV DNA polymerase, the enzyme that is necessary for the virus to replicate in liver cells. Viread has been available in the United States as a treatment for HIV infection in adults since 2001. (East Bay Business Times, CA)
Invitrogen posts profit for last quarter of '07 Feb 8, 2008
Invitrogen will obtain a license from Agilent and pay an undisclosed royalty to sell its DNA polymerase blend products. The company said it expects the benefit in the fourth quarter of 2008 from legal settlements to be $8 million. (San Diego Union-Tribune -- Business)
Adaptive expression responses in the Pol-gamma null strain of S. pombe depleted of mitochondrial genome Sep 15, 2007
DNA polymerase gamma (Pol-gamma) has been shown to be essential for maintenance of the mitochondrial genome (mtDNA) in the petite-positive budding yeast Saccharomyces cerevisiae. Budding yeast cells lacking mitochondria exhibit a slow-growing or petite-colony phenotype. (BioMed Central)
Distinct energetics and closing pathways for DNA polymerase betawith 8-oxoG template and different incoming nucleotides Feb 22, 2007
Distinct energetics and closing pathways for DNA polymerase beta with 8-oxoG template and different incoming nucleotidesYanli Wang and Tamar Schlick ... 8-Oxoguanine (8-oxoG) is a common oxidative lesion frequently encountered by DNA polymerases such as the repair enzyme DNA polymerase beta (pol beta). (BioMed Central)
